Serratus Plane Block and Pectointercostal Block

Comparison of Deep Serratus Plane Block With Deep Serratus Plane Block+Pectointercostal Plane Block

ASA I-II female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. Patients will divide into 2 groups. Deep serratus plane block will perform with 0,25 %bupivacaine 20 ml at the midaxillary 5. rib, bilaterally for Group I. At Group II, deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally . General anesthesia with sevoflurane and remifentanil will perform to the all patients. Postoperative pain scores, morphine consumption and complications will record till the 24.th hours.

Study Overview

• Status: Recruiting
• Conditions: Postoperative Pain
• Intervention / Treatment: Procedure: ultrasound guided Serratus plane bock; Procedure: ultrasound guided Serratus plane bock and pectointercostal block

Detailed Description

ASA I-II female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. General anesthesia with sevoflurane and remifentanil will perform to the all patients. Patients will divide into 2 groups. Serratus plane block for group I and serratus plane block+pectointercostal block for Group II will perform bilaterally. Ultrasound guided deep serratus plane block will perform with 0,25% bupivacaine 20 ml at the midaxillary 5. rib, for Group I. At Group II, ultrasound guided deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally. Patient controlled analgesia will perform with Morphine ( 1 mg bolus+ 10 min lockout+4 hours limit 10 mg) at postoperative period. Patients will evaluate with visual analogue scale (VAS) for postoperative pain scores till the first 24.th hours. Postoperative pain scores (VAS), morphine consumption and complications will record till the 24.th hours.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ebru Biricik; Phone Number: 05052420223; Email: ebrubiricik01@gmail.com

Study Locations

• Turkey
  • Adana, Turkey
    • Recruiting
    • Cukurova University Faculty of Medicine
    • Contact: Ebru Biricik; Phone Number: 05052420223; Email: ebrubiricik01@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ASA I-II patients
• Female
• who will undergoing Breast reduction surgery

Exclusion Criteria:

• ASA III and over patients
• who reject to join the study
• male gender

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Serratus plane block; Deep serratus plane block will perform with 20 ml 0,25 %bupivacaine at the midaxillary 5. rib, bilaterally	Procedure: ultrasound guided Serratus plane bock; ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib to the all patients
Active Comparator: Serratus plane block+pectointercostal plane block; deep serratus plane block (20 ml 0,25 %bupivacaine) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally .	Procedure: ultrasound guided Serratus plane bock and pectointercostal block; ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib and pectointercostal plane block (0,25% bupivacaine 15 ml) will perform at 4-5.th intercostal space. Both 2 blocks will perform bilaterally

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
postoperative morphine consumption	Patient controlled analgesia with morphine will perform to the all patients and morphine consumption will calculate and record till the end of 24.th hours.	All the patients will follow till the postoperative 24.th hours and totally morphine consumption will record postoperative 24.th hours.
postoperative visual analog scale scores	All the patients will evaluate with visual analog scale scores (VAS) at the first postoperative 24.th hours period. VAS scores will define between 0-10 scores. 0 score means lowest pain score and 10 means the worst pain score.	VAS scores will record at the first postoperative 24.th hours

Collaborators and Investigators

• Sponsor: Cukurova University
• Investigators: Principal Investigator: Ebru Biricik, Cukurova University Faculty of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): May 10, 2024
• Primary Completion (Estimated): August 10, 2024
• Study Completion (Estimated): August 10, 2024

Study Registration Dates

• First Submitted: April 19, 2024
• First Submitted That Met QC Criteria: April 19, 2024
• First Posted (Actual): April 24, 2024

Study Record Updates

• Last Update Posted (Actual): May 13, 2024
• Last Update Submitted That Met QC Criteria: May 10, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative
• Other Study ID Numbers: Serratus-Pectointercostal

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No